,"Authors: Wilkins, Martin Russell; Wilkins, M. R.",,,,,,,,,,,
,,,,,,,,,,,,
,"h index = 21 (Of the 60 documents considered for the h-Index, 21 have been cited at least 21 times.)",,,,,,,,,,,
,Note: The h Index considers Scopus documents published after 1995.  ,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,<2007,2007,2008,subtotal,>2008,total
Publication Year,Document Title,Authors,ISSN,Journal Title,Volume,Issue,1194,245,196,441,156,1791
2009,"Therapeutic targets in pulmonary arterial hypertension","Rhodes C.J., Davidson A., Gibbs J.S.R., Wharton J., Wilkins M.R.",01637258,"Pharmacology and Therapeutics",121, 1,0,0,0,0,2,2
2008,"Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension","Baliga R.S., Zhao L., Madhani M., Lopez-Torondel B., Visintin C., Selwood D., Wilkins M.R., MacAllister R.J., Hobbs A.J.",1073449X,"American Journal of Respiratory and Critical Care Medicine",178, 8,0,0,0,0,2,2
2008,"Emerging concepts and translational priorities in pulmonary arterial hypertension","Michelakis E.D., Wilkins M.R., Rabinovitch M.",00097322,"Circulation",118, 14,0,0,0,0,5,5
2008,"Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension","Nickel N., Gibbs J.S.R., Hoeper M.M., Wollert K.C., Kempf T., Tapken H., Tongers J., Laenger F., Lehmann U., Golpon H., Olsson K., Wilkins M.R.",1073449X,"American Journal of Respiratory and Critical Care Medicine",178, 5,0,0,0,0,3,3
2008,"Phosphodiesterase inhibitors for the treatment of pulmonary hypertension","Wilkins M.R., Wharton J., Grimminger F., Ghofrani H.A.",09031936,"European Respiratory Journal",32, 1,0,0,5,5,15,20
2008,"Circulating endothelial progenitor cells in patients with eisenmenger syndrome and idiopathic pulmonary arterial hypertension","Diller G.-P., Bauersachs J., Hobbs A.J., Wilkins M.R., Gatzoulis M.A., Wharton J., Van Eijl S., Okonko D.O., Howard L.S., Ali O., Thum T., Wort S.J., Bedard E., Gibbs J.S.R.",00097322,"Circulation",117, 23,0,0,2,2,7,9
2008,"Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland","Gibbs J.S.R., Black C., Elliot C., Fisher A.J., Handler C., Howard L., Hughes R., Jenkins D.P., Johnson M., Lordan J., MacGowan G., Coghlan G., Morrell N., Schulze-Neick I., Sheares K., Wilkins M., Wort J., Crozier A., Das C., De Soyza J., Doherty S., Flynn Y., Corris P.A., Gin-Sing W., Harries C., Rootes M., Carroll G., Armstrong I., Trembath R., Gaine S., Gatzoulis M.A., Haworth S.G., Kiely D.G., Peacock A., Pepke-Zaba J.",13556037,"Heart",94, 1,0,0,2,2,5,7
2007,"Treating acute myocardial infarction: something in the wind?","Bogle R., Wilkins M.",01406736,"Lancet",370, 9597,0,0,0,0,0,0
2007,"Emerging therapies for pulmonary arterial hypertension","Ali O., Wharton J., Gibbs J.S.R., Howard L., Wilkins M.R.",13543784,"Expert Opinion on Investigational Drugs",16, 6,0,1,1,2,1,3
2007,"Noninvasive and invasive evaluation of pulmonary arterial pressure in highlanders","Kojonazarov B.K., Imanov B.Z., Amatov T.A., Mirrakhimov M.M., Naeije R., Wilkins M.R., Aldashev A.A.",09031936,"European Respiratory Journal",29, 2,0,2,2,4,1,5
2006,"Genome-wide scan for premature hypertension supports linkage to chromosome 2 in a large Kyrgyz family","Kalmyrzaev B., Aldashev A., Khalmatov M., Polupanov A., Jumagulova A., Mamanova L., Wilkins M.R., Town M.",0194911X,"Hypertension",48, 5,0,1,3,4,0,4
2006,"Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension","Abdul-Salam V.B., Paul G.A., Ali J.O., Gibbs S.R., Rahman D., Taylor G.W., Wilkins M.R., Edwards R.J.",16159853,"Proteomics",6, 7,2,4,2,6,4,12
2006,"Genetic association of the serotonin transporter in pulmonary arterial hypertension","Machado R.D., Hoeper M., Fijalkowska A., Kurzyna M., Thomson J.R., Gibbs S.R., Wilkins M.R., Seeger W., Morrell N.W., Gruenig E., Trembath R.C., Koehler R., Janssen B., Glissmeyer E., Veal C., Suntharalingam J., Kim M., Carlquist J., Town M., Elliott C.G.",1073449X,"American Journal of Respiratory and Critical Care Medicine",173, 7,6,7,5,12,8,26
2006,"Cannabis and cannabis-based medicines: Potential benefits and risks to health","Wilkins M.R.",14702118,"Clinical Medicine, Journal of the Royal College of Physicians of London",6, 1,0,0,0,0,1,1
2005,"Phosphodiesterase type 5 and high altitude pulmonary hypertension","Aldashev A.A., Kojonazarov B.K., Amatov T.A., Sooronbaev T.M., Mirrakhimov M.M., Morrell N.W., Wharton J., Wilkins M.R.",00406376,"Thorax",60, 8,7,14,5,19,1,27
2005,"Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension","Paul G.A., Gibbs J.S.R., Boobis A.R., Abbas A., Wilkins M.R.",03065251,"British Journal of Clinical Pharmacology",60, 1,25,13,19,32,9,66
2005,"Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells","Wharton J., Strange J.W., Moller G.M.O., Growcott E.J., Ren X., Franklyn A.P., Phillips S.C., Wilkins M.R.",1073449X,"American Journal of Respiratory and Critical Care Medicine",172, 1,19,18,14,32,13,64
2005,"Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study","Wilkins M.R., Pennell D.J., Mohiaddin R.H., Nihoyannopoulos P., Gibbs J.S.R., Paul G.A., Strange J.W., Tunariu N., Gin-Sing W., Banya W.A., Westwood M.A., Stefanidis A., Ng L.L.",1073449X,"American Journal of Respiratory and Critical Care Medicine",171, 11,55,33,22,55,15,125
2005,"Warfarin: A case history in pharmacogenetics","Hall A.M., Wilkins M.R.",13556037,"Heart",91, 5,3,3,2,5,1,9
2005,"Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension","Khoo J.P., Zhao L., Alp N.J., Bendall J.K., Nicoli T., Rockett K., Wilkins M.R., Channon K.M.",00097322,"Circulation",111, 16,11,15,11,26,4,41
2005,"cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling","Phillips P.G., Long L., Wilkins M.R., Morrell N.W.",10400605,"American Journal of Physiology - Lung Cellular and Molecular Physiology",288, 1,17,8,6,14,6,37
2004,"Selective or Nonselective Endothelin Receptor Blockade in Pulmonary Arterial Hypertension","Wilkins M.R.",00030805,"American Journal of Respiratory and Critical Care Medicine",169, 4,1,1,0,1,0,2
2003,"Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension","Sebkhi A., Strange J.W., Phillips S.C., Wharton J., Wilkins M.R.",00097322,"Circulation",107, 25,60,18,20,38,6,104
2003,"Bosentan: Profile report","Rubin L.J., Wilkins M.R., Paul G.",11720360,"Drugs and Therapy Perspectives",19, 1,0,0,0,0,0,0
2003,"Pulmonary arterial hypertension and the vasoconstrictive factor: Is there still a role for vasodilator testing?","Gibbs J.S.R., Wharton J., Wilkins M.R.",0195668X,"European Heart Journal",24, 4,2,1,0,1,0,3
2003,"Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity","Zhao L., Mason N.A., Strange J.W., Walker H., Wilkins M.R.",00097322,"Circulation",107, 2,27,9,7,16,3,46
2002,"Characterization of high-altitude pulmonary hypertension in the Kyrgyz: Association with angiotensin-converting enzyme genotype","Aldashev A.A., Wilkins M.R., Morrell N.W., Sarybaev A.S., Sydykov A.S., Kalmyrzaev B.B., Kim E.V., Mamanova L.B., Maripov R., Kojonazarov B.K., Mirrakhimov M.M.",1073449X,"American Journal of Respiratory and Critical Care Medicine",166, 10,18,10,7,17,2,37
2002,"Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: A human PET study with [11C]WAY-100635 and [11C]raclopride","Rabiner E., Gunn R.N., Wilkins M.R., Sedman E., Grasby P.",02698811,"Journal of Psychopharmacology",16, 3,9,7,1,8,3,20
2002,"5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-Chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl] -1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: A [11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl) ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans","Rabiner E.A., Wilkins M.R., Turkheimer F., Gunn R.N., De Haes J.U., De Vries M., Grasby P.M.",00223565,"Journal of Pharmacology and Experimental Therapeutics",301, 3,12,1,3,4,2,18
2002,"Developments in therapeutics for pulmonary arterial hypertension","Wilkins M.R., Moller G.M.O., Ren X., Wharton J.",00264725,"Minerva Cardioangiologica",50, 3,4,0,0,0,1,5
2002,"Nitric oxide, phosphodiesterase inhibition, and adaption to hypoxic conditions","Wilkins M.R., Aldashev A., Morrell N.W.",01406736,"Lancet",359, 9317,8,2,1,3,0,11
2002,"Natriuretic peptide receptors and the heart","King L., Wilkins M.R.",13556037,"Heart",87, 4,5,1,2,3,0,8
2002,"Recent insights into the pathogenesis and therapeutics of pulmonary hypertension","Strange J.W., Wharton J., Phillips P.G., Wilkins M.R.",01435221,"Clinical Science",102, 3,24,1,0,1,1,26
2002,"Phosphodiesterase inhibition in the treatment of pulmonary hypertension","Sebkhi A., Phillips P.G., Strange J., Wharton J., Wilkins M.R.",01973118,"Cardiovascular Reviews and Reports",23, 5,0,0,0,0,0,0
2001,"Progress in, and future prospects for, the treatment of primary pulmonary hypertension","Wilkins M.R., Wharton J.",13556037,"Heart",86, 6,3,1,0,1,1,5
2001,"Sildenafil inhibits hypoxia-induced pulmonary hypertension","Zhao L., Mason N.A., Morrell N.W., Kojonazarov B., Sadykov A., Maripov A., Mirrakhimov M.M., Aldashev A., Wilkins M.R.",00097322,"Circulation",104, 4,176,37,22,59,8,243
2001,"Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries","Jourdan K.B., Mason N.A., Long L., Philips P.G., Wilkins M.R., Morrell N.W.",10400605,"American Journal of Physiology - Lung Cellular and Molecular Physiology",280, 6,9,2,0,2,2,13
2001,"Genetic and molecular mechanisms of pulmonary hypertension","Morrell N.W., Wilkins M.R.",14702118,"Clinical Medicine",1, 2,2,0,0,0,0,2
2001,"Right ventricular hypertrophy secondary to pulmonary hypertension is linked to rat chromosome 17: Evaluation of cardiac ryanodine Ryr2 receptor as a candidate","Zhao L., Sebkhi A., Nunez D.J.R., Long L., Haley C.S., Szpirer J., Szpirer C., Williams A.J., Wilkins M.R.",00097322,"Circulation",103, 3,14,0,2,2,0,16
2000,"Sildenafil inhibits hypoxia-induced pulmonary hypertension in mice","Zhao L., Mason N.A., Wilkins M.R.",00406376,"Thorax",55, 3,0,0,0,0,0,0
2000,"The type 3 phosphodiesterase inhibitor, cilostamide, attenuates acute and chronic hypoxia-induced pulmonary hypertension","Phillips P.G., Long L., Wilkins M.R., Morrell N.W.",00406376,"Thorax",55, 3,0,0,1,1,0,1
2000,"Drug action at the 5-HT(1A) receptor in vivo: Autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-11C]WAY- 100635","Rabiner E.A., Gunn R.N., Wilkins M.R., Sargent P.A., Mocaer E., Sedman E., Cowen P.J., Grasby P.M.",09698051,"Nuclear Medicine and Biology",27, 5,19,6,4,10,1,30
2000,"Vascular remodeling and ET-1 expression in rat strains with different responses to chronic hypoxia","Aguirre J.I., Morrell N.W., Long L., Clift P., Upton P.D., Polak J.M., Wilkins M.R.",00029513,"American Journal of Physiology",278, 5,23,0,3,3,0,26
1999,"Phosphodiesterase isoenzyme expression in rat pulmonary artery smooth muscle cells and the effect of phosphodiesterase inhibition on cellular proliferation","Phillips P.G., Long L., Wilkins M.R., Morrell N.W.",00406376,"Thorax",54, 3,0,0,0,0,0,0
1999,"Genetic determination of cardiac mass in normotensive rats results from an F344 x WKY cross","Sebkhi A., Zhao L., Lu L., Haley C.S., Nunez D.J.R., Wilkins M.R.",0194911X,"Hypertension",33, 4,23,3,0,3,0,26
1999,"NPR-A-deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension","Zhao L., Long L., Morrell N.W., Wilkins M.R.",00097322,"Circulation",99, 5,36,1,3,4,1,41
1998,"Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts","Redondo J., Bishop J.E., Wilkins M.R.",00071188,"British Journal of Pharmacology",124, 7,28,1,4,5,4,37
1998,"A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients","Hoglund C., Cifkova R., Mimran A., Tenczer J., Watt A., Wilkins M.R., Lindberg E.",00086312,"Cardiology",89, 4,9,0,1,1,1,11
1998,"The prevalence of alcohol misuse in patients undergoing cataract surgery","Davis A.R., Wilkins M., Dew T., Sherwood R., Coakes R., Peters T.J.",13556215,"Addiction Biology",3, 2,2,0,0,0,0,2
1997,"Effect of endothelin on protein synthesis in smooth muscle cells from rat pulmonary microvasculature","Long L., Morrell N., Redondo J., Wharton J., Wilkins M.R.",00406376,"Thorax",52, 6,0,0,0,0,0,0
1997,"Effect of sponge size, type and application technique on tissue uptake of 5-fluorouracil","Wilkins M.R., Occleston N., Walers L., Kotecha A., Pa T.K.",01460404,"Investigative Ophthalmology and Visual Science",38, 4,0,0,0,0,0,0
1997,"Downregulation of natriuretic peptide C-receptor protein in the hypertrophied ventricle of the aortovenocaval fistula rat","Brown L.A., Rutherford R.A.D., Nunez D.J.R., John Wharton, Lowe D.G., Wilkins M.R.",00086363,"Cardiovascular Research",36, 3,9,0,0,0,0,9
1997,"The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice","Clifford C.P., Adams D.A., Murray S., Taylor G.W., Wilkins M.R., Boobis A.R., Davies D.S.",00316970,"European Journal of Clinical Pharmacology",52, 4,35,2,3,5,0,40
1997,"A randomised, double-blind trial comparing mibefradil and amlodipine: Two long acting calcium antagonists with similar efficacy but different tolerability profiles","Viskoper R.J., Bernink P.J.L.M., Schelling A., Ribeiro A.B., Kantola I.M., Wilkins M.R., Kobrin I.",09509240,"Journal of Human Hypertension",11, 6,18,0,0,0,0,18
1997,"The natriuretic-peptide family","Wilkins M.R., Redondo J., Brown L.A.",01406736,"Lancet",349, 9061,97,7,4,11,7,115
1996,"Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung","Zhao L., Al-Tubuly R., Sebkhi A., Owji A.A., Nunez D.J.R., Wilkins M.R.",00071188,"British Journal of Pharmacology",119, 6,30,0,2,2,1,33
1996,"Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat","Kirk J.E., Wilkins M.R.",00071188,"British Journal of Pharmacology",119, 5,5,0,0,0,0,5
1996,"Adrenomedullin activity in chronically hypoxic rat lungs","Zhao L., Brown L.A., Owji A.A., Nunez D.J.R., Smith D.M., Ghatei M.A., Bloom S.R., Wilkins M.R.",03636135,"American Journal of Physiology - Heart and Circulatory Physiology",40, 2,1,1,0,1,2,4
1996,"Adrenomedullin activity in chronically hypoxic rat lungs","Zhao L., Brown L.A., Owji A.A., Nunez D.J.R., Smith D.M., Ghatei M.A., Bloom S.R., Wilkins M.R.",03636135,"American Journal of Physiology - Heart and Circulatory Physiology",271, 2,25,1,0,1,0,26
1996,"The regulation of pulmonary vascular tone","Wilkins M.R., Zhao L., Al-Tubuly R.",03065251,"British Journal of Clinical Pharmacology",42, 1,9,0,0,0,1,10
1995,"Letter to the editor [6]","Gray P.J., Moore C., Bourke R.D., Cooling R.J., Elliott A.J., Davis A., Wilkins M.",0950222X,"Eye",9, 6,1,0,0,0,0,1
1995,"Renal response to candoxatrilat in patients with heart failure","Good J.M., Peters M., Wilkins M., Jackson N., Oakley C.M., Cleland J.G.F.",07351097,"Journal of the American College of Cardiology",25, 6,31,1,1,2,0,33
1995,"Selective increase in endothelin-1 and endothelin A receptor subtype in the hypertrophied myocardium of the aorto-venacaval fistula rat","Brown L.A., Nunez D.J., Brookes C.I.O., Wilkins M.R.",00086363,"Cardiovascular Research",29, 6,29,0,2,2,0,31
1994,"Failure of topical bupivacaine to relieve pain after vitreoretinal surgery [12]","Davis A., Wilkins M., Elliott A.J.",0950222X,"Eye",8, 6,1,0,0,0,0,1
1994,"Inhibition of nitric oxide synthesis in vascular smooth muscle by retinoids","Hirokawa K., O'Shaughnessy K.M., Ramrakha P., Wilkins M.R.",00071188,"British Journal of Pharmacology",113, 4,39,1,1,2,0,41
1994,"Induction of nitric oxide synthase in cultured vascular smooth muscle cells: The role of cyclic AMP","Hirokawa K., O'Shaughnessy K., Moore K., Ramrakha P., Wilkins M.R.",00071188,"British Journal of Pharmacology",112, 2,46,0,0,0,0,46
1994,"Identification of renal natriuretic peptide receptor subpopulations by use of the non-peptide antagonist, HS-142-1","Rutherford R.A.D., Matsuda Y., Wilkins M.R., Polak J.M., Wharton J.",00071188,"British Journal of Pharmacology",113, 3,7,1,0,1,1,9
1993,"Endopeptidase-24.11 and its inhibitors: Potential therapeutic agents for edematous disorders and hypertension","Wilkins M.R., Unwin R.J., Kenny A.J.",00852538,"Kidney International",43, 2,28,0,0,0,1,29
1993,"Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat","Brown L.A., Nunez D.J.R., Wilkins M.R.",00219738,"Journal of Clinical Investigation",92, 6,49,5,1,6,1,56
1993,"Effect of endopeptidase-24.11 inhibition and of atrial natriuretic peptide clearance receptor ligand on the response to rat brain natriuretic peptide in the conscious rat","Kirk J.E., Wilkins M.R.",00071188,"British Journal of Pharmacology",110, 1,5,0,0,0,0,5
1993,"Assessemtn of ?-adrenoceptor selectivity of bunazosin retard in man","Clifford P., Unwin R.J., Dollery C.T., Wilkins M.R.",03065251,"British Journal of Clinical Pharmacology",35, 5,0,0,0,0,0,0
1992,"A comparison of the effects of the selective peripheral ?1-blocker terazosin with the selective ?1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension","Ligueros M., Unwin R., Wilkins M.R., Humphreys J., Coles S.J., Cleland J.",09599851,"Clinical Autonomic Research",2, 6,0,0,0,0,1,1
1992,"Arginine derivative and uraemia [30]","Taylor G., Unwin R., Wilkins M., Capasso G.",01406736,"Lancet",339, 8803,1,0,0,0,0,1
1992,"Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat","Wilkins M.R., Settle S.L., Kirk J.E., Taylor S.A., Moore K.P., Unwin R.J.",00071188,"British Journal of Pharmacology",107, 1,6,0,0,0,0,6
1991,"Selective ?1-adrenoreceptor blockers in the treatment of hypertension: Should we be using them more?","Ligueros M., Unwin R., Wilkins M.",09599851,"Clinical Autonomic Research",1, 3,0,0,0,0,0,0
1991,"Renal synthesis of atriopeptin-like protein in physiology and pathophysiology","Greenwald J.E., Needleman P., Wilkins M.R., Schreiner G.F.",00029513,"American Journal of Physiology - Renal Fluid and Electrolyte Physiology",260, 4,21,3,0,3,0,24
1990,"Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure","Wilkins M.R., Settle S.L., Stockmann P.T., Needleman P.",00278424,"Proceedings of the National Academy of Sciences of the United States of America",87, 16,27,1,0,1,2,30
1990,"Alternative mechanisms for atriopeptin prohormone processing by isolated perfused rat hearts","Toki Y., Ito T., Shiono S., Siegel N.R., Gierse J.K., Wilkins M.R., Needleman P.",00223565,"Journal of Pharmacology and Experimental Therapeutics",254, 1,1,0,0,0,0,1
1990,"Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation","Wilkins M.R., Settle S.L., Needleman P.",00219738,"Journal of Clinical Investigation",85, 4,14,1,0,1,0,15
